Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In general I agree, although those that were accomplices to NP (i.e. Kelly) may be persona non grata at the FDA. We may have more changes ahead…
It won’t be a year - give it a month or two (maybe three). They need to sort through the data (which may be part of the Amarex process) and develop a coherent strategy. I want to hear what they HAVE done, not the NP promise of what they MAY do.
“the company will act like a legit biotech”
I agree. We have adults in charge now, which includes keeping quiet until they achieve a catalyst or are required to report. I don’t buy into the partnership/buyout fantasies. I have gone through enough senior management turnovers to know there will be an internal process of realignment. The new CEO will need to sort through the data to prioritize resources (staff and financial). We are in for an extended quiet period.
NP deserves all the blame and then some. Telling the CRO to submit an insufficient BLA alone warrants all the blame. Not implementing a quality assurance/control plan to manage the CRO warrants blame. Misleading shareholders with dubious analysis on trial results, forcing the FDA to make a counter statement warrants blame. Misleading shareholders on the incomplete BLA and selling his own shares warrants blame. There are more reasons, but those alone are enough to not only place blame but likely warrant criminal charges.
Truth is stranger than fiction, and in the case of CYDY truth is stranger than childrens’ fiction.
This quiet period may be a plea bargain process that includes a smooth transition to new management. Nader could win a reduced sentence, shareholders save some value, Amarex is more likely to get paid, and Sidley gets paid and keeps a long term valued client. My experience with legal issues is the attorney fees are always a consideration.
“Who is selling at this price?” Easy explanations;
1. Those that don’t trust management and think the SP is going lower.
2. Those that can offset capital losses.
3. Those that bought below the current SP (like all the cheap warrants Nader has given his buddies).
If only those results were published in a peer reviewed journal rather than spewed on a Proactive Video by a con man.
“The emails I’m interested in are those from NP directing his platoon of paid pumpers, led by Mike Sheikh. “
I’m not an attorney, but wouldn’t this potentially go from insider trading to racketeering?
My only concern about that is I would expect the investigation to take longer. We need these guys gone sooner rather than later!
Think about the emails we haven’t seen….yet. That email was not written in a vacuum. No doubt there are emails either advising for or against, and/or questioning that decision or decisions like it. We may not have access to those other emails, but the FBI certainly does.
Ops, you are so focused on getting the 200M, without regard at all to who the BOD will be. Giving 200M shares to a board that has squandered the opportunity to this point doesn’t make sense.
Take a stand on management!
Vote Nader and Kelly and Naydenov out!!!!!!
It’s no wonder Nader worked so much harder blocking the 13 D than he did getting the BLA filed accurately - he was going to be exposed. Now these crooks are using our money to hire lawyers to defend themselves!!
We can’t wait for the Feds, they need to be voted off the board.
“I wouldn’t be surprised if SK flips on NP for the DOJ. “
It will definitely be an interesting game of prisoners dilemma. The question is how much Nader has on Kelly. I suspect Kelly is playing checkers while Nader is playing chess. Either way, they both need to go and the sooner the better.
Vote Nader and Kelly off the board!
I appreciate that we have different perspectives. I have started three buisness. Two of those were delivering services in a government regulated industry. Both were mult-million revenue when they were sold. One to private owners and one to VC. As a CEO, the idea that I would direct staff to submit an incomplete regulatory document is unfathomable. The idea that that the motivation is based on short term stock price - and worse bulletin board comments - is utterly outrageous.
As a retired CEO, Nader’s action is frightening. But even more frightening are the things we don’t know about….yet. This kind of behavior is never singular.
….better yet, you should think for yourself. If you want to give more money to a CEO, and board member, who intentionally files an incomplete BLA, sells his shares, and lies to investors, well, that is certainly your prerogative. I believe Op’s advice is counter to basic business fundamentals.
Your reply proves my point. You place all the blame on 13D, and don’t hold management accountable at all.
Arguing to give a lying, cheating CEO (that the market doesn’t trust) another 200M shares? You can wax poetically about your experience, but your advice doesn’t pass buisness fundamentals 101. Peter Drucker is rolling over in his grave with that kind of advice!
The first thing this company needs is to vote NP off the board, and ideally SK and JN as well. Separate the BOD from management!
For a guy that claims to have as much buisness experience as you do I am struck by the focus on the 200M shares with little to no message on how to actually improve management.
Here is my take: if we keep current management this stock goes belly up. Therefore, first and foremost we need to vote NP, SK, and JN off the board. Then and only then do we approve additional shares. If that means a reverse split - so be it. We need to rip the festering band-aid off the infected wound and any way you do it it is going to hurt.
If you really want to protect this investment focus on the problem, not the symptom.
Nader has one job. That is to get a BLA approved. If he didn’t know the status of the submission he is not fit to be CEO.
You can’t dance and pussyfoot around the responsibility, particularly when he is paid $10M/yr. If he paid half the attention to the BLA that he did to cutting of the 13D we wouldn’t be here.
Vote NP, JN, and SK off the board. If they deserve to stay as employees (except JN) let the new board make that decision.
Sword, You are not the only no vote. I voted no on everything! If NP is off the board I’ll consider additional shares, if JN is off, I’ll consider more, and if those two and SK are off I’d give them the 200M.
actually, imPOTUS is inept. First HCQ, then disinfectant and light therapy, oleandrin, now plasma. The “stable genius” is neither stable nor genius and has dismally responded to the covid crisis.
the simplest explanation that leronlimab hasn’t been approve for Covid is that the placebo controlled and blinded trial data hasn’t been released and reviewed by the FDA. If we have sufficient results and they don’t move us towards approval (a phase three trial could be possible) then I’ll listen to conspiracy theories- until then, let’s get the data.
Well... I’d like to trade places with you, I would be much wealthier with your numbers. The question was if we got approval for Covid. The market discounts all other indications significantly (thus the current price) and the assumption is based on $2B revenue. Here are my numbers;
Earnings are 40% of $2B (10% to manufacturing and 50% to distributors- I think that was the Vyera deal)
$800M earnings/500M shares = $1.6/share
Assume P/E of 22, 22x 1.6 = $35/share
As I said it could be +/- $15/share depending on assumptions. Given how the market has treated CYDY, I think that is roughly where we would end up. If we have other catalysts the numbers change.
It’s possible.....Nader mentioned revenue potential of $2B. Conventional valuation methods with relatively modest assumptions could put the price in that range (give or take $15/share).
A woman on the CYDY FB site suggested a Roth conversion (I wish I was that smart) which got me thinking and I pulled the trigger. If you believe the stock will rise more than your initial tax hit, and you have the cash for Uncle Sam, I think it makes sense ——. That said, we are all in different situations and consult your accountant before hand.
I moved my CYDY from a traditional IRA to a Roth. My understanding is you are taxed on the value of the stock at market close the day you convert. My accountant made sure I understood there was no going back and no tax deduction in the event the stock drops.
I would suggest a little study of Cost/Benefit analysis and game theory. I believe you would be able to answer your own question.
I hope Tuesday- I’d like another buying opportunity on Monday.
You should call Ameritrade. In some cases these companies make you jump through a hoop to trade OTC. Vanguard made me do the first trade on the phone and then I had electronic access.
They could stop the trial if the effectiveness of the drug was so clearly superior to placebo that continuing the trial would result in unnecessary deaths. I suspect that the trial would have to be much larger than ours, for the statistics to be that dramatic. Also, I suspect the FDA folks to be overwhelmed and our trial is a smaller one that likely is a lower priority given their limited resources.
No, not even close.
Post the data - not a Fox News clip. I read the Ford study from them directly. You can take HCQ based on a retrospective (non blinded study), I will trust my health to double blinded studies like the WHO is using.
Management transition terms in a buyout would be more generous than the 18 months in the 8k. The buyer generally offers existing management a sweet offer to help facilitate overall negotiations. The cost of management is negligible relative to the overall deal.
I am five minutes away as well and considering going. My only hesitation is being in large groups right now - perhaps they could give each registrant 2 vials just in case?
There is as much data in that statement as the hydroxy studies referenced!!!
This is the big hope for new investors and share price increase on CYDY????? LMFAO!!!
“Did you see where the HCQ is by far the most preferred by doctors overall worldwide out of list of 15 others?”
What is the source (with link) for this claim?
It is better that he doesn't mention Leronlimab - lest it be lumped in with the other recommendations. It is much better to let the trials/science speak for itself.
I'm new on the board, but long since $0.60 and adding. I am more interested in long term validation and revenue than short term bumps.